ev-201: enfortumab an option for cisplatin-ineligible advanced uc | arjun balar
Published 3 years ago • 120 plays • Length 4:15Download video MP4
Download video MP3
Similar videos
-
2:58
ev-201: enfortumab vedotin for cisplatin-ineligible bladder cancer
-
1:06
treatment options for patients who progress on enfortumab vedotin | arjun balar
-
3:14
the role of enfortumab vedotin in earlier lines and stages of urothelial cancer | arjun balar
-
5:23
ev in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer
-
2:20
ev-201: enfortumab vedotin for bladder cancer
-
6:01
ev-201, ev-301 and unite: enfortumab vedotin in advanced urothelial cancer
-
4:38
ev-301: enfortumab vedotin boosts advanced urothelial cancer survival | thomas powles
-
0:35
ev-302: 1l enfortumab vedotin in combination with pembrolizumab
-
11:29
enfortumab vedotin plus pembrolizumab: results of the ev-302 trial with thomas powles, md
-
8:07
long term outcome of enfortumab vedotin pembrolizumab in first line locally advanced or metast...
-
3:32
livanova perceval valve preparation for implantation
-
1:58
enfortumab vedotin for the treatment of advanced urothelial cancer
-
2:09
ev-103: neoadjuvant enfortumab vedotin in cis-ineligible mibc
-
1:58
novel agent enfortumab, a nectin-4 inhibitor, for bladder tcc: asco 2018 highlights (bmic-049)
-
0:34
pembrolizumab plus enfortumab vedotin for bladder cancer
-
1:09
dr. balar on improved outlook in metastatic bladder cancer
-
0:54
dr. balar on biomarkers of immunotherapy response in bladder cancer
-
16:47
metastatic urothelial cancer: clinical insights into trial data | shilpa gupta and petros grivas
-
0:54
dr. balar on results of keynote-052 in urothelial cancer
-
9:03
nectin4 amplification predicts response to ev in metastatic urothelial carcinoma